COVID-19 infection and thrombosis.
COVID-19
Coagulopathy
Hypercoagulability
LMWH
Thrombosis
Journal
Clinica chimica acta; international journal of clinical chemistry
ISSN: 1873-3492
Titre abrégé: Clin Chim Acta
Pays: Netherlands
ID NLM: 1302422
Informations de publication
Date de publication:
Nov 2020
Nov 2020
Historique:
received:
08
05
2020
revised:
10
06
2020
accepted:
21
07
2020
pubmed:
28
7
2020
medline:
29
10
2020
entrez:
27
7
2020
Statut:
ppublish
Résumé
Recent reports on outbreak of SARS-CoV-2 coronavirus (COVID-19) have shown its association with abnormal blood clots. The viral infection initiates inflammatory responses leading to endothelial damage and coagulation cascade dysfnction. Spread of COVID-19 has been associated with disseminated intravascular coagulation (DIC) and subsequent coagulopathy. Initially coagulopathy in COVID-19 patients result in significant elevation of D-dimer, fibrin/fibrinogen degradation products (FDP), and abnormalities in coagulatory parameters, which resulting in formation of thrombus and eventually death. Present report intends to summarize the information of the research reports available so far on the complications of formation of unusal blood clots (thrombosis) during COVID-19 infection and its therapeutic strategies. Extensive web search was done for various reports associating COVID-19 infection with increased coagulopathy and abnormal coagulatory parameters such as PT, PTT, and platelet counts; along with increased D-dimer and fibrinogen levels. Findings of these research reports were summarized to recommend cautions for clinicians while treating COVID-19 patient. Screening of coagulatory parameters upon admission and during entire course of treatment is recommended, especially those who are at increased risk of thrombosis. Also, anticoagulant treatment can be used as thromboprophylaxis measure. Dose and duration of anticoagulation treatment requirement may vary and thus regular monitoring is needed.
Sections du résumé
BACKGROUND
BACKGROUND
Recent reports on outbreak of SARS-CoV-2 coronavirus (COVID-19) have shown its association with abnormal blood clots. The viral infection initiates inflammatory responses leading to endothelial damage and coagulation cascade dysfnction. Spread of COVID-19 has been associated with disseminated intravascular coagulation (DIC) and subsequent coagulopathy. Initially coagulopathy in COVID-19 patients result in significant elevation of D-dimer, fibrin/fibrinogen degradation products (FDP), and abnormalities in coagulatory parameters, which resulting in formation of thrombus and eventually death.
METHODOLOGY
METHODS
Present report intends to summarize the information of the research reports available so far on the complications of formation of unusal blood clots (thrombosis) during COVID-19 infection and its therapeutic strategies. Extensive web search was done for various reports associating COVID-19 infection with increased coagulopathy and abnormal coagulatory parameters such as PT, PTT, and platelet counts; along with increased D-dimer and fibrinogen levels.
RESULTS AND CONCLUSION
CONCLUSIONS
Findings of these research reports were summarized to recommend cautions for clinicians while treating COVID-19 patient. Screening of coagulatory parameters upon admission and during entire course of treatment is recommended, especially those who are at increased risk of thrombosis. Also, anticoagulant treatment can be used as thromboprophylaxis measure. Dose and duration of anticoagulation treatment requirement may vary and thus regular monitoring is needed.
Identifiants
pubmed: 32712049
pii: S0009-8981(20)30370-3
doi: 10.1016/j.cca.2020.07.046
pmc: PMC7377993
pii:
doi:
Substances chimiques
Anticoagulants
0
Types de publication
Letter
Langues
eng
Sous-ensembles de citation
IM
Pagination
344-346Informations de copyright
Copyright © 2020 Elsevier B.V. All rights reserved.
Références
Circ Res. 2016 Apr 29;118(9):1392-408
pubmed: 27126649
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Br J Haematol. 2020 Jun;189(5):846-847
pubmed: 32304577
J Thromb Haemost. 2020 Apr;18(4):844-847
pubmed: 32073213
Haematologica. 1999 Mar;84(3):254-9
pubmed: 10189392
Eur J Clin Invest. 1997 Jan;27(1):3-9
pubmed: 9041370
J Thromb Haemost. 2020 Jun;18(6):1521-1522
pubmed: 32302456
Semin Thromb Hemost. 2001 Dec;27(6):619-31
pubmed: 11740685
JAMA Intern Med. 2020 Jul 1;180(7):934-943
pubmed: 32167524
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
J Thromb Haemost. 2020 Jun;18(6):1421-1424
pubmed: 32271988
Thromb Haemost. 1999 Aug;82(2):695-705
pubmed: 10605770
Semin Thromb Hemost. 2001 Dec;27(6):605-17
pubmed: 11740684
Thromb Haemost. 1997 Jul;78(1):415-9
pubmed: 9198189
Antimicrob Agents Chemother. 2016 Oct 21;60(11):6532-6539
pubmed: 27550352
N Engl J Med. 1999 Aug 19;341(8):586-92
pubmed: 10451465
BMJ. 2020 Mar 26;368:m1091
pubmed: 32217556
Cardiovasc Res. 2003 Oct 15;60(1):26-39
pubmed: 14522404
Jpn J Pharmacol. 1984 Jul;35(3):203-27
pubmed: 6482087
J Intensive Care. 2014 Mar 06;2(1):20
pubmed: 25520834
Lancet Haematol. 2020 Jun;7(6):e438-e440
pubmed: 32407672
J Thromb Haemost. 2020 May;18(5):1094-1099
pubmed: 32220112